trending Market Intelligence /marketintelligence/en/news-insights/trending/9wPoFJ96DgX-DrbQC3yiSA2 content esgSubNav
In This List

Report: Mallinckrodt seeks sale of generic drug unit

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Report: Mallinckrodt seeks sale of generic drug unit

Mallinckrodt PLC is looking at the possibility of a sale of its generic drug unit, Reuters reported May 30, citing "people familiar with the matter."

A deal for the unit might be valued at about $2 billion. There is no guarantee the talks will lead to a deal, according to the sources.

The company has reportedly appointed Credit Suisse Group AG to run a sale process for the business.